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Abstract 
BTM are useful in clinical practice as they are inexpensive and they have proven useful for 
treatment monitoring and identification of poor adherence. BTM cannot be used in 
individual patients for identifying accelerated bone loss or an increase in fracture risk or in 
Page 1 of 32
 Accepted Preprint first posted on 18 October 2017 as Manuscript EJE-17-0585
 Copyright © 2017 European Society of Endocrinology.


deciding on the optimal therapy. They are useful for monitoring both anti-resorptive and 
anabolic treatment. Response can be defined as a result that exceeds an absolute target, or 
by a change  greater than the least significant change; if such a response is not present, then 
poor compliance or secondary osteoporosis are likely causes. A baseline BTM measurement 
is not always made; in that case, a value of BTM on anti-resorptive treatment that is low or 
low normal or above the reference interval for anabolic therapy may be taken to indicate 
satisfactory response. We provide an approach to using these bone turnover markers in 
clinical practice by describing algorithms for anti-resorptive and anabolic therapy and 
describing the changes we observe in the clinical practice setting. 
 
Introduction 
 
The fractures that result from osteoporosis are a major public health problem (Eastell 
2016 
1
). Osteoporosis is characterised by reduced bone mass and microarchitectural 
deterioration leading to increased bone fragility and may be diagnosed by measurement of 
bone mineral density (BMD) using dual-energy x-ray absorptiometry. A BMD value at the 
spine or hip that is 2.5 standard deviations or more below the average value for healthy 
young women is considered to represent osteoporosis, according to the WHO Working 
Group. Several treatments have been licensed for use in osteoporosis that are effective in 
reducing the risk of fracture..  
 
 This article focuses on the use of bone turnover markers (BTM) in osteoporosis. BTM 
can be measured in serum, plasma and urine and their levels relate to the activity of 
osteoblasts (bone formation markers) and osteoclasts (bone resorption markers). Bone 
formation markers include proteins that are specific to bone (osteocalcin), or not so specific 
to bone such as fragments of type I procollagen released during formation of type I collagen 
(N-propeptide of type I collagen, PINP) and the bone isoform of alkaline phosphatase (bone 
ALP). Bone resorption markers include fragments released from the telopeptide (end) 
region of type I collagen following its enzymatic degradation, including the N-telopeptide of 
type I collagen (NTX) and the C-telopeptide of type I collagen (CTX), deoxypyridinoline and 
the enzyme tartrate resistant acid phosphatase (Table 1). 
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In women, the BTMs increase after the menopause and in other situations of 
accelerated bone loss. In men, there is little increase with age. In cohort studies of women 
(but not of men), the higher the BTM, the more rapid the bone loss and the greater the risk 
of fracture. Thus, the measurement of BTM may have clinical relevance to the individual. 
Currently, the main clinical use for BTM is for the monitoring of response to therapy. A 
typical goal of therapy might be to lower BTM to values found in women before the 
menopause. 
 
History, assays and validation 
Bone histomorphometry is the gold standard for assessment of bone turnover, but it is 
invasive, cannot be repeated many times in an individual and requires specialist laboratory 
interpretation.  Bone turnover can also be quantified with calcium balance and kinetic 
studies, but they are time-consuming, use radio-isotopes and again need specialist 
interpretation. 
 
Therefore, for clinical use in large numbers of patients there is a need for measures that 
can be made on easily accessible samples (single measurements of blood or urine), 
inexpensively, don’t require time-consuming specialist processing, and give results that can 
be interpreted by non-specialist health care practitioners.  
 
The BTM that were developed initially were not bone-specific (for example, 
hydroxyproline and total alkaline phosphatase), the assays were technically challenging 
(HPLC for total deoxypyridinoline) and therefore costly and difficult to implement widely. 
The newer BTM are more bone-specific and the use of enzyme-linked immunosorbent 
assays (ELISA) and autoanalyser techniques have made them widely available and more 
affordable (Table 1). 
 
 
 
Although assays for total alkaline phosphatase (ALP) were available in the 1920s, only 
about half of the total ALP is from bone. Hydroxyproline assays were developed in the 
1950s, but again were not specific for bone, and were laborious and dangerous (they 
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resulted in explosions). There were significant developments in the 1980s and 1990s with 
assays for pyridinium crosslinks (deoxypyridinoline and pyridinolone), bone ALP, PINP and 
osteocalcin and progression from HPLC to immunoassays. 
 
The introduction of automated immunoassay analysers in 2000 was a major technical 
advance. These are widely used in clinical practice for measuring many analytes, including 
hormones, as well as BTM and they do so with high precision (CV less than 5%) and 
reliability.  
 
 
BTM have been validated against gold standard methods for studying bone turnover 
such as a comparison with tracer kinetics and bone histomorphometry, both in health 
(Eastell 1988 
2
) and in response to osteoporosis treatments (Eastell 1997 
3
).  Currently-used 
BTM were evaluated in a study of 370 women with osteoporosis (Chavassieux 2015 
4
). BTM 
were assessed against dynamic histomorphometry of iliac crest biopsies. There were weak 
to moderate correlations (highest r-value was 0.41) between the bone formation markers 
PINP or bone ALP and bone formation estimates, and between CTX and bone resorption 
estimates.  
 
 
Practical aspects 
There are different requirements for the use of BTM in clinical practice compared to the 
research setting. In clinical practice, patients may attend appointments at any time of day 
and there may be a delay before samples are transported to the laboratory. Patients often 
have complex medical problems and take multiple medications. In this context, some 
properties of BTM present challenges to their clinical use. 
 
BTM need to be measured reliably and easily, be locally accessible, inexpensive and be 
unaffected by the time of day the samples are obtained. 
 
The bone resorption markers show a strong circadian rhythm and decrease shortly after 
feeding. Thus, it is recommended that blood samples for CTX be drawn from the patient 
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following an overnight fast between 0730 and 1000 (Szulc 2017 
5
). The sample can be 
collected as EDTA plasma or serum; EDTA is preferable if the sample cannot be processed 
within 2 hours. The sample can be stored frozen until measured; if the storage is likely to be 
more than 12 weeks, it is recommended that this is at -70 to -80° C (Okabe 2001 
6
). It is 
recommended for urinary NTX that the sample is taken as the second morning void, that 
excessive fluid consumption is avoided and preservative is not added. Variability can be 
further reduced by obtaining urine samples on three consecutive days, pooling the samples 
and just making one measurement. As well as measuring the bone resorption marker (NTX, 
CTX, DPD), it is usual to measure urinary creatinine and to express the result as the BTM to 
creatinine ratio to correct for urinary dilution.  
 
For bone formation markers, there is a weaker circadian rhythm and so the sample can be 
drawn at any time of the day (Szulc 2017 
5
). Serum or plasma should be measured the same 
day or stored in the freezer until measured (Szulc 2017 
5
). EDTA plasma should not be used 
for bone ALP measurement (Szulc 2017 
5
). Osteocalcin is affected by haemolysis which can 
lead to a falsely low result. BTM, especially bone formation markers, are increased following 
fracture and are affected by some medical conditions and treatments, as discussed below 
(Szulc 2017 
5
). 
 
 
 
Choice of BTM 
It is logical to include a bone resorption and a bone formation assay when evaluating 
bone turnover. The choice of BTM will be determined by local availability and cost. It will 
also be determined by the clinical picture. Thus, in chronic kidney disease, the markers that 
are usually excreted by the kidney circulate at very high levels and so markers that are not 
excreted by the kidney are best used, e.g. Bone ALP and intact PINP. In the evaluation of 
glucocorticoid treatment on bone, markers that are sensitive to the bone effects of these 
drugs may be most useful, e.g. osteocalcin and PINP which are affected in a dose-dependent 
manner. These markers are not, however,  useful to evaluate the effect of anti-resorptive 
therapy in these patients.  
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The IOF has proposed serum CTX and PINP as the two reference markers; they propose 
that all research studies should include these two at a bare minimum (Vasikaran 2011 
7
), but 
for clinical practice it may suffice to have one marker only. 
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Potential Clinical Utility 
 
BTM have proven useful in evaluating the relationship between bone turnover and rates of 
bone loss, fracture risk and treatment effect in groups of patients using statistical 
approaches including linear and logistic regression or repeated measures analysis of 
variance. However, different statistical approaches are needed to evaluate the utility of 
BTM in the individual. These include tests of diagnostic accuracy (sensitivity, specificity) and 
assessment of the least significant change to identify response. The least significant change 
is a change (expressed in absolute units or percentage) that is beyond the day to day 
changes observed in untreated individuals. It is a statistical approach and is often defined 
and allows for change up or down and beyond the change expected 95% of the time. It is 
widely used in clinical chemistry where it is also referred to in some texts as the ‘Reference 
Critical Difference’ (Fraser 
8
). It is calculated as 2.77 times the coefficient of variation; the 
latter includes both assay and within-subject variability.  
 
Prediction of bone loss 
High bone turnover is associated with more rapid bone loss in postmenopausal women 
(Shieh 2016 
9
) and BTM have been studied in evaluation this relationship. Higher BTM are 
associated with bone loss from both trabecular and cortical bone at the hip; and also relate 
to greater periosteal expansion in the femoral neck (Marques 2016 
10
). The assessment is 
improved by making more than one BTM measurement (Ivaska 2008 
11
). Estimation of the 
rate of bone loss in a postmenopausal woman when deciding about her need for anti-
resorptive treatment would potentially be useful. Unfortunately, the association between 
BTM and bone loss is not sufficient to classify individuals reliably by their BTM level (Rogers 
2000 
12
). 
 
 
Prediction of fracture 
It would also be of interest to estimate the risk of fracture in the individual 
postmenopausal woman when deciding about the need for anti-resorptive treatment and 
high bone turnover is associated with increased risk of several types of fracture in both men 
and women (Vilaca 2017 
13
, Vasikaran 2011 
7
).  In a recent meta-analysis of 6 studies that 
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had measurements of bone resorption (CTX) and bone formation (PINP), the hazard ratio 
per SD increase was similar for CTX (1,18, 95% CI 1.05 to 1.34) and PINP (1.23, 95% CI 1.09-
1.39)(Johansson 2014 
14
). These results were not adjusted for BMD. However, not all studies 
find an association between BTM and fracture risk (Marques 2016 
10
) and the FRAX Position 
Development Conference members were unable to find sufficient evidence for inclusion of 
BTM into the FRAX fracture risk prediction algorithm (McCloskey 2011 
15
).  
 
 
Selection of therapy 
 
Intuitively, we would like to choose our therapies based on the mechanism of bone loss 
underlying the osteoporosis. Thus, we might use anti-resorptive therapies 
(bisphosphonates, raloxifene, denosumab) in patients with high BTM and anabolic therapies 
(teriparatide, abaloparatide) in patients with low BTM. Unfortunately, this approach is not 
supported by the results of clinical trials. In the Fracture Intervention Trial, treatment with 
alendronate was more effective at reducing non-vertebral fracture in those women with 
higher PINP but this was not true for other BTM or other fracture types (Bauer 2006 
16
). 
Similarly, the baseline BTM did not predict the fracture benefit with teriparatide (Delmas 
2006 
17
). In general, a low PINP is associated with lower rates of bone loss and lower 
response to zoledronic acid. (Eastell 2015 
18
) Further research is needed. 
 
 
Treatment used for osteoporosis 
Despite having several treatments that reduce the risk of fracture in osteoporosis it is well 
established that adherence to these treatments can be poor, especially in the case of oral 
bisphosphonates for which the dosing instructions are complex. There is therefore a need to 
identify optimal treatment response in individual patients. It has been proposed that 
treatment failure may be considered if two or more fractures occur on treatment (Diez Perez 
2012 
19
) based on evidence from clinical trials of drugs for osteoporosis in which there is a 
large reduction in risk for spine and hip fracture, although the reduction in risk of other 
fractures is lower. In practice, the occurrence of two or more fractures during treatment is a 
very rare event. Bone mineral density is commonly used as a tool to monitor treatment in 
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the individual and an increase that exceeds the least significant change, for example an 
increase in lumbar spine or total hip BMD more than 4% (Diez Perez 2012 
19
) may be 
considered a response. However, such changes occur over many months and persistence 
with medication declines very early in treatment (less than 50% after 12 months, 
Netelenbos 2011 
20
) so an earlier response marker would be preferred. The International 
Osteoporosis Foundation has proposed that a BTM such as PINP or CTX measured within 3 
months of starting therapy would help identify poor adherence with the commonest 
osteoporosis therapy, oral bisphosphonates (Diez Perez 2017 
21
).  Another advantage to 
using BTM rather than bone mineral density is that measurements are less expensive. In our 
hospital setting, a PINP measurement costs less than 20% that of a bone mineral density 
measurement. Finally, BTM may be a better surrogate for fracture risk reduction than BMD. 
The proportion of treatment effect explained by BTM has usually been higher than for BMD 
(Vasikaran 2011 
7
). 
 
Bisphosphonate 
Bisphosphonates are the most commonly-used drugs for osteoporosis. There are three oral 
bisphosphonates that are licensed in most countries, namely alendronate, risedronate and 
ibandronate. The absorption of the oral bisphosphonates is very poor and as the dosing 
regimen is complex, many patients do not comply fully with the instructions so do not 
achieve an optimal response even though they may take their medication regularly. The oral 
bisphosphonates have been compared in the TRIO study (Clinical Trial Number:  
NCT00666627)(Naylor 2015 
22
) to evaluate the clinical utility of BTM to assess response. 
Alendronate and ibandronate decreased BTM (CTX, NTX) more than risedronate. In this 
study, more than 80% of patients responded to treatment as defined by a decrease more 
than the LSC for CTX (56%) and PINP (38%) after 3 months of treatment. Response can also 
be defined as a reduction to a level below the mean found in healthy young women (Naylor 
2015 
22
). In one study, the mean values were given as 217 to 317 ng/L for CTX and 32 to 38 
μg/L for PINP (Morris 2017
23
).. In the assessment of treatment response in the individual, 
the magnitude of the decrease has also been found to be important; for example, with 
alendronate (Bauer 2004 
24
) and risedronate (Eastell 2003 
25
) the greater the reduction in 
BTM, the greater the reduction in vertebral fracture risk.  
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Zoledronic acid is given by annual intravenous infusion, thus avoiding concerns about 
poor absorption. It results in a reduction in CTX by 2 weeks and when it is given for 6 years 
as in the Horizon Study, the suppression of CTX and PINP is maintained (Black 2015 
26
). PINP 
was found to be even better than CTX and BMD in the Horizon study at identifying clinical 
(fracture) efficacy and responders (Bell 2016 
27
). As with the oral treatments, the greater the 
reduction in PINP with zoledronic acid, the greater the reduction in the risk of vertebral 
fractures (Jacques 2012 
28
).  
 
 
 
Denosumab 
Denosumab inhibits bone resorption, leading to an early and large decrease in bone 
resorption markers followed by a later and smaller decrease in bone formation markers. 
Bone resorption markers (such as CTX) decrease within 24 hours of treatment. In the 
FREEDOM Study, there was no overlap in CTX levels between treated and control subjects at 
one month indicating that everyone appears to respond (Eastell 2011 
29
). Denosumab results 
in a greater inhibition of bone resorption than zoledronic acid (Miller 2016 
30
). PINP 
decreases over several months to a lesser extent than the bone resorption markers and 
remains suppressed with continued dosing for up to 8 years (Papapoulos 2015 
31
). Once the 
drug is stopped, the BTM overshoot so that their levels are increased compared to baseline 
(Bone 2011 
32
). These high BTM results are associated with accelerated bone loss and there 
are recent reports of multiple vertebral fractures associated with this high BTM (Lamy 2017 
33
). 
 
  
 
 
 
SERMs 
Selective receptor oestrogen agonists (SERM) such as raloxifene have a weaker effect on 
bone turnover than bisphosphonates and denosumab. Even so, their effect can be 
monitored using BTM. In 60 to 65% of women with osteopenia, a significant response could 
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be demonstrated using the LSC approach with CTX or PINP (Naylor 2016 
34
). The BTM 
response to raloxifene was greatest in those with greatest adherence (Finigan 2013 
35
) 
providing further support for use of BTM as a means of identifying poor adherence to 
therapy (see below). 
 
 
 
 
 
Teriparatide 
Teriparatide is an anabolic agent administered as a daily subcutaneous injection and 
bone formation markers increase within days of starting treatment (Glover 2009 
36
), peaking 
by 3 months. PINP has proven to be the most responsive BTM to this treatment. Most 
patients have a significant response using PINP and an increase greater than the LSC (of 
more than 10 μg/L, Krege 2014 
37
) may be used to identify responders. The change in BTM 
relates to the later change in BMD (Niimi 2014 
38
). Poor BMD response is associated with low 
BTM at baseline (PINP, NTX) or smaller increase in BTM after 4 months on treatment (Niimi 
2016 
39
). 
The licence for teriparatide is for 2-years as there is a concern about osteosarcoma with 
long-term use and the effect of the drug wanes after three years of therapy. There is 
accelerated bone loss after stopping teriparatide, but this can be prevented by administering 
bisphosphonates, raloxifene or denosumab (Ebina 2016 
40
).  
Abaloparatide is a new licensed anabolic therapy for osteoporosis (Shirley 2017 
41
). It is a 
synthetic peptide analogue of the human parathyroid hormone-related protein and works 
through the PTH receptor as does teriparatide. However, the increase in PINP is less than 
with teriparatide (Miller 2016 
42
). The clinical utility of BTMs for monitoring abaloparatide 
therapy have not yet been fully reported. 
 
 
Practical approach to monitoring 
We have been using BTM to monitor osteoporosis therapy in our secondary care practice 
for 20 years. We have observed that many patients commencing treatment and having a 
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poor BTM response are identified as having minor errors in following the dosing instructions 
that may not be picked up by a brief medication review. This is particularly important as 
most osteoporosis medication prescribing takes place in general practice by non-specialists 
who may not appreciate the limited absorption of oral bisphosphonates and the need for 
complete and consistent adherence to the dose regime. In primary care, time and resource 
to undertake early assessment of compliance is also limited and so we felt it appropriate to 
roll out the approach of monitoring osteoporosis therapy using BTM into general practice.  
Figure 1 illustrates the algorithm that has been implemented in clinical practice. The 
physician decides to treat; most commonly, this would be with an oral bisphosphonate such 
as alendronate. At this point, PINP is measured. Our local laboratory uses the automated 
immunoassay (Roche Cobas) for this measurement; the results are similar for other 
automated immunoassays (IDS iSYS)(Morris 2017
23
, Table 2); we need more data on the 
Orion PINP assay in comparison to the other assays. In one study, the results were similar 
(Eastell 2012 
43
) but in another the Orion assay give results lower than either Roche or IDS 
(Cavalier, personal communication). A discussion is held with the patient after one month to 
assess compliance and any problems or concerns with their treatment. This discussion is 
often held over the phone and may be initiated by their doctor, nurse or a pharmacist. The 
PINP measurement is repeated after 6 months to assess response. Treatment response is 
defined as a decrease in PINP that exceeds the least significant change of 10 μg/L or a 
decrease to below the geometric mean for young women (35 μg/L). As we describe later, 
the management advice accompanying the algorithm highlights factors such as incident 
fracture that may affect the interpretation of the PINP result and the actions to take if a 
clear response is not identified. 
CTX can be used in the same way as for PINP for monitoring in practice and it has the 
advantage of the change being earlier than for PINP (Naylor 2015 
22
). The mean CTX value is 
280 ng/L (Morris 2016
23
) and the least significant change value is about 100 ng/L (in Table 2 
it is 60 to 80 ng/L depending on the method).  
The estimates of least significant change (and the geometric means) are based on the 
assay and within-subject variability and so are a statistical approach and can be used for the 
monitoring of any intervention on bone turnover.  
The mean values for PINP and CTX for the population were based on values obtained 
from studies in Italy, UK, France, Belgium, USA, UK, Saudi Arabia and Denmark (Morris 2016 
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23
); there don’t appear to be important differences between countries (Glover 2009 
44
) and 
so they should be suitable for international use. The mean values for PINP using Roche and 
IDS assays is probably similar (Morris 2016 
23
, Table 2). However, the mean values for CTX 
used to be higher for IDS (Table 2, Eastell 2012 
43
) but more recent reports show them to be 
lower (Morris 2016
23
). There is a clear need for harmonisation of assay results for BTMs 
(Vasikaran 2011 
7
). 
 
Treatment targets 
The rationale for choosing a least significant change of 10 μg/L is that changes up to this 
level could occur by chance in up to 95% of people whereas a change greater than this is 
relatively uncommon and it is based on untreated postmenopausal women with low bone 
mineral density (Eastell 2006 
45
). The least significant change is also similar for both the 
Roche Cobas and the IDS iSYS assays as too is the mean response to oral bisphosphonates 
(Table 2). 
The rationale for choosing a target PINP value of <35 μg/L is that in clinical trials of anti-
resorptive drugs the lowest fracture risk is found in those women with bone turnover 
marker levels on treatment below the average value for young women (Eastell 2007 
46
, 
Delmas 2009 
47
). Bone turnover markers have a skewed distribution, so it is best to take the 
geometric mean or the median. This value is around 35 μg/L for the Roche Cobas assay 
(Morris 2016
23
). The critical values for PINP (and CTX) are supported by results from those 
obtained in 50 women from the TRIO study with postmenopausal osteoporosis treated with 
oral bisphosphonate and compared to 200 healthy young control women. It can be seen 
from Table 2 that the mean values for young women are similar for PINP and close to 35 
μg/L for both assays. It can also be seen that the least significant change is similar and as the 
baseline PINP was around 46 μg/L, an LSC of 23% equivalent to about 10 μg/L. It is also 
notable that the mean reduction on treatment after 12 to 13 weeks is very similar. The 
attraction of using PINP rather than CTX can be seen from this table - the LSC is lower for 
PINP than CTX and PINP does not need to be taken in the fasting state. 
 
The concepts of least significant change and target for treatment are not unique to the 
use of bone turnover markers in osteoporosis and so are already familiar to colleagues in 
primary care. In type 2 diabetes, it is usual to monitor with haemoglobin A1c and consider 
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the reference change value (the same as least significant change) and the target; the critical 
values used are 0.5% change and a target of 7.0% (Little 2011 
48
).  
 
Sources of variability in BTMs  
 
Many clinical factors influence BTM measurements but we pay particular attention to 
the occurrence of a fracture or to treatment with glucocorticoids as these are common 
confounders and have a clinically important impact. There is a large increase in PINP after a 
fracture, with a mean increase of 55% six weeks after wrist fracture (Ingle 1999 
49
), 96% six 
weeks after ankle fracture (Ingle 1999 
50
) and 100% 12 weeks after tibial shaft fracture 
(Veitch 2006 
51
). BTMs have also been report to be increased after vertebral fracture 
(Hashidate 2011 
52
). The magnitude of the increase appears to relate to the bone size at the 
site of fracture and may be greater if the fracture is managed surgically. Many patients 
initiate osteoporosis therapy in the weeks following a fracture and in the GLOW study, 7% of 
patients taking osteoporosis medication for 3 years sustained an incident fracture, 
illustrating the importance of this effect (Diez-Perez 2014 
53
).  
Glucocorticoid therapy reduces the level of PINP in a dose-responsive manner and this 
also makes the interpretation of PINP difficult - is any reduction due to a beneficial effect of 
bisphosphonate treatment or due to the harmful effect of the glucocorticoid? For example, a 
daily dose of 10 mg prednisone resulted in a 20% reduction in PINP over a week. Thus, PINP 
is only helpful in monitoring treatment of glucocorticoid-induced osteoporosis if the 
glucocorticoid dose is established and remains stable. If accessible, it may be preferable to 
use another BTM in this clinical situation, such as bone ALP, CTX or NTX. 
 
 
Evaluation of use in clinical practice 
 Antiresorptive Therapy 
 
We introduced the monitoring algorithm (Figure 1) into primary care in Sheffield in 
September 2011 and conducted an audit on all patients being evaluated for osteoporosis at 
the Metabolic Bone Centre in Sheffield in July 2012. New treatment was recommended to 
the general practitioner in 108 cases (mean age 65 years, 86% female) and baseline PINP 
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was obtained by the GP in 76 of these. Follow-up measurement was made in 34 of these. 
We found that at follow-up, 27 (79%) met the criteria for treatment response (Figure 2).  
Among the 7 people with poor response, we found reasons for this in 3 cases (poor 
compliance, intercurrent surgery and the sample measured too early). We were encouraged 
by this early uptake of PINP monitoring and are working further to develop awareness 
among general practitioners and to develop confidence in its use. 
 
We acknowledge that monitoring using PINP in clinical practice is by necessity pragmatic, 
needing to minimise cost and patient inconvenience and differs considerably from the 
research approach. Nonetheless, the approach has been welcomed by GP colleagues and we 
believe is preferable to no monitoring or reassessment of BMD after 2 years, by which time a 
high proportion of patients have stopped treatment.  
 
The interpretation of PINP results and the need to change treatment needs to be 
considered on an individual basis using clinical judgement and considering factors such as 
the severity of the osteoporosis, likelihood of poor compliance (e.g. presence of dementia) 
and presence of known confounders. 
In all patients with suboptimal response, especially if repeat PINP remains increased, 
change in treatment needs to be considered. We would often move onto parenteral 
treatment at this point to eliminate problems due to poor compliance and/or poor 
absorption. 
Our initial evaluation of the use of PINP for monitoring anti-resorptive therapy in clinical 
practice (Figure 2) drew our attention to several types of responses. 
 
 
Black – a significant decrease to below 35µg/L 
This is consistent with a good response to a level that is associated with low fracture risk 
and so is the optimal response. We would recommend the physician confirms compliance, 
enquires about any drug side-effects and encourages the patient to continue therapy and 
report any new issues. Medications should be reviewed at least annually and risk 
assessment including DXA planned at 5 years. Further PINP measurement is not considered 
necessary unless the clinical situation alters. 
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Red – a significant decrease but not to below 35µg/L  
 Many patients like this will have high baseline BTM. The high PINP on treatment may 
indicate that fracture risk is still somewhat elevated (Eastell 2006 
46
, Delmas 2012 
47
) and the 
patient may benefit from treatment with a parenteral drug such as zoledronic acid or 
denosumab. 
 A high baseline PINP may be due to fracture within the preceding 6-12 months, 
especially if very recent. In that case, any subsequent decrease may be due to the 
healing fracture and so does not indicate good response.  Thus, it is important to 
check compliance and if this is adequate then continue with treatment and repeat 
PINP in another 3 months. If PINP is still above 35 then consider investigation for 
secondary osteoporosis. 
 A high baseline PINP may occur in a patient with another disease affecting PINP e.g. 
skin disease, liver dysfunction. Consider if an additional confounder has developed 
and if investigations are indicated; check compliance and repeat in another 3 
months. If uncertainty remains at that point, consider change in treatment. 
 
Yellow – no significant change and remains under 35µg/L  
 Low PINP values are associated with a lower risk of fracture. It is not certain whether 
patients with low BTM have fracture benefit from treatment – one study with 
alendronate would indicate there is no benefit (Bauer 2006 
16
) whereas a study with 
risedronate indicates there may be some benefit (Siebel 
54
). Certainly, patients with 
low PINP tend to have low rates of bone loss when left untreated and low BMD 
increases in response to anti-resorptive treatment (Eastell 2015 
18
). Nonetheless, 
continued treatment would generally be considered appropriate and the patient may 
be advised that the BTM result indicates a low risk of fracture. 
 
Green – a significant increase in PINP, to above 35µg/L  
 This is likely to reflect either an intercurrent event leading to an increase in bone 
turnover or presence of a disease that provides a non-bone source of PINP 
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 A common cause of increased PINP is a new fracture (magnitude of increase 
related to size of bone affected) with an additional impact from surgical 
intervention. If a fracture is confirmed, then check the compliance, reassure the 
patient that a fracture occurring very early in treatment is not due to treatment 
failure and reassess after another 3-6 months 
 Other causes include a reduction in glucocorticoid dose since treatment 
initiation, ie with greater suppression of PINP at baseline when on a higher dose 
– if the 6 month result remains above 35µg/L this still suggests poor treatment 
response. In practice, we would measure another marker unaffected by 
glucocorticoid 
  at this point eg NTX and if result is low then presume response 
 May be due to new secondary osteoporosis eg development of thyrotoxicosis – 
clinical evaluation and relevant investigation should be undertaken and any 
underlying cause treated. Compliance with the osteoporosis treatment should 
also be checked and encouraged. 
 We may observe fluctuations in PINP (and other BTM) in patients with co-
morbidities especially those affecting liver, kidney and skin. For example, 
increases in PINP are observed after non-bone surgical intervention reflecting 
PINP from type I collagen in skin. In these patients, check compliance and 
consider using another marker 
 
If there remains a suboptimal response then a change to an alternative agent such a 
parenteral drug (zoledronic acid or denosumab) may be considered. If there is a good BTM 
response, but the patient has one or more new vertebral fractures, then a change to an 
anabolic drug (teriparatide) may be considered. 
 
 
Monitoring offset of effect in the individual 
 
It is often recommended that oral bisphosphonate therapy is stopped after 5 years in milder 
forms of osteoporosis (Adler 2016 
55
). The rationale for this is that longer-term therapy may 
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increase the risk of atypical femur fractures and once treatment is stopped there is 
continued benefit with little bone loss from the spine and continued (if mild) suppression of 
bone turnover (Black 2006 
56
). Attempts have been made to monitor the offset of effect with 
BMD, but the changes at the hip are quite small relative to the least significant change and 
so only a small proportion of patients are identified as having offset of effect, with just 29% 
having more than 5% bone loss from the total hip 5 years after stopping alendronate 
(McNabb 2013 
57
). BTM could be used for this purpose, perhaps using the LSC approach to 
examine for an increase or the threshold approach to identify a value that is above the mean 
for young women and so merits re-starting therapy. There has been little published on this 
topic and there appears to be little association between change in BMD or BTM and fracture 
risk off treatment with alendronate (Bauer 2014 
58
). We await further research before 
making any recommendations.  
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Anabolic Therapy 
We also use PINP to assess response to teriparatide treatment. Teriparatide is used in 
patients with severe and complicated osteoporosis so it is important to consider if response 
is optimal as early as possible, particularly as treatment is limited to 24 months. Suboptimal 
response may be due to issues with compliance, drug storage or injection technique.   
We evaluated 91 patients monitored using PINP.  All had previously been treated with 
anti-resorptive therapy, mean age 71 years (89% female). The baseline PINP was 35 μg/L 
using the Roche Cobas automated immunoassay analyser, reflecting the effect of the prior 
anti-resorptive treatment. We took our treatment targets as an increase of more than the 
least significant change in PINP at months one and three (10 μg/L)(Eastell 2006 
45
) and an 
increase to above the reference interval of 69 μg/L (Glover 2008 
59
) on at least one occasion. 
We found that by 3 months of treatment 93% exceeded the least significant change and 66% 
exceeded the upper limit of the reference interval (Figure 4). This responder rate of 93% was 
similar to that found in clinical trials of teriparatide of 87, 77, and 87% (McClung 2005 
60
, 
Neer 2001 
61
, Tsujimoto 2011 
62
). There was no significant correlation between PINP results 
and change in lumbar spine BMD at two years but this was difficult to evaluate as only 29% 
of our patients had reliable spine scans due to very high prevalence of vertebral fracture and 
degenerative change. The baseline PINP in this evaluation were low as all patients had 
previously been treated with anti-resorptive drugs and so these findings not relevant to 
patients starting teriparatide with no such prior therapy. 
 
In our experience, treatment is often commenced without measurement of a baseline 
PINP, especially in primary care. In this situation, it is particularly important to undertake a 
thorough evaluation of adherence to treatment and we find it remains valuable to make the 
6 month measurement. A PINP value on treatment that is low or low normal for anti-
resorptive treatment (ie <35 µg/L) or above the reference interval for anabolic therapy (ie 
>69 µg/L) may be presumed to indicate adequate response. However, this approach is less 
well documented than the least significant change approach. 
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Current recommendations: Examples 
The IOF and IFCC made recommendations concerning BTM and reviewed national 
guidelines; five out of nine national societies or organisations recommended the use of BTM 
for treatment monitoring, although recognising that further research and evaluation 
remains necessary (Vasikaran 2011 
7
).  
The IOF proposed that a PINP or CTX value at 12 weeks on treatment with oral 
bisphosphonate can identify poor response and be used to identify patients who are 
unlikely to be adhering to therapy (Diez-Perez 2017 
21
) or who have failed therapy (Diez-
Perez 2013). The IOF proposed using the BTMs at 12 weeks rather than 3 months on 
treatment and the responder rate in the TRIO study was similar for 12 and 48 weeks (Naylor 
2015 
22
) and so this approach is appropriate. National guidelines supporting the use of bone 
turnover markers are also available, such as those from and Austrian Group and from the 
Japanese Osteoporosis Society (Bieglmayer 2012 
63
, Nishizawa 2013 
64
). 
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Figure legends 
 
 Figure 1. Sheffield PINP monitoring algorithm for anti-resorptive treatment. Optimal 
treatment response with PINP is a decrease of 10 μg/L to below 35 μg/L. Optimal treatment 
response with CTX is a decrease of 100 ng/L to below 280 ng/L. 
 
 
 Figure 2. Serum PINP (μg/L) measured using Roche Cobas in patients starting anti-
resorptive therapy in 34 patients based in general practice setting. Solid lines indicate 
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response with a significant change in PINP to a level below 35 μg/L, and dotted lines no 
response. The lines are coloured red to indicate those patients who had a significant change 
in PINP but didn’t reach the target, yellow to indicate those who reached the target but 
PINP didn’t change, and green to show an increase in PINP. The second PINP value should 
have been taken after 6 months of treatment and the broken horizontal line shows the 
critical value of 35 μg/L (the mean value of PINP in healthy young women). 
 
 
 Figure 3. Sheffield PINP monitoring algorithm for anabolic treatment. An optimal 
response would be an increase in PINP of more than 10 ug/L to above 69 μg/L. 
 
 
 Figure 4. The absolute value of PINP (μg/L) measured using Roche Cobas at baseline, 
one and three months after starting teriparatide in 91 people for osteoporosis. The blue 
dashed horizontal line represents the upper limit of the reference interval for healthy young 
women (69 μg/L). Overall, 95% responded with an increase of more than 10 μg/L above 
baseline at both 1 and 3 months and 66% exceeded the upper limit of the reference interval 
at at least one timepoint. Patients meeting both response criteria, i.e. demonstrating an 
optimal response, are shown in black; those who had a significant increase in PINP but not 
exceeding the reference interval are shown in red. Patients in whom no BTM response was 
demonstrated are shown in green. The extremely high value of PINP of more than 500 μg/L 
was observed in a patient with auto-immune hepatitis. 
Page 26 of 32
	




	


 




 



!




"!
#$
% 
 & '
 (
"($'  



)* +

"!
#
$
%  & '
 	

#
#"
+*'
  !,+)* +


"%  & '
	


 $



"$-'
 




)* +

"!
#
$
%  & '
 



"-'
 




)* +

"(#

$
%
'
 %
.
"%%' / 0*$


)* +

 
#
#1
 



)* +

"%  & '


Page 27 of 32
	


	 !	
					"
	
	
""
#$%	&
'(()'**#


	"	"	(()'	
	
+(

,

-  
- .%%/%  
	
0((
.%%/%  
	
0((
1
12"3$
+,
"3$+,
)( )) )* (
$%14 5 ) 0 
$%12"3$
"3$
6 * 7 6
8
14 9( 90 9* 9*0
8
12"3$
"3$
97 9) 905 9)6


Page 28 of 32
)LJXUH6KHIILHOG3,13PRQLWRULQJDOJRULWKPIRUDQWLUHVRUSWLYHWUHDWPHQW
2SWLPDOWUHDWPHQWUHVSRQVHZLWK3,13LVDGHFUHDVHRIǌJ/WREHORZ
ǌJ/2SWLPDOWUHDWPHQWUHVSRQVHZLWK&7;LVDGHFUHDVHRIQJ/WREHORZ
QJ/ 
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)LJXUH6HUXP3,13ǌJ/PHDVXUHGXVLQJ5RFKH&REDVLQSDWLHQWV
VWDUWLQJDQWLUHVRUSWLYHWKHUDS\LQSDWLHQWVEDVHGLQJHQHUDOSUDFWLFHVHWWLQJ
6ROLGOLQHVLQGLFDWHUHVSRQVHZLWKDVLJQLILFDQWFKDQJHLQ3,13WRDOHYHOEHORZ
ǌJ/DQGGRWWHGOLQHVQRUHVSRQVH7KHOLQHVDUHFRORXUHGUHGWRLQGLFDWH
WKRVHSDWLHQWVZKRKDGDVLJQLILFDQWFKDQJHLQ3,13EXWGLGQ¶WUHDFKWKHWDUJHW
\HOORZWRLQGLFDWHWKRVHZKRUHDFKHGWKHWDUJHWEXW3,13GLGQ¶WFKDQJHDQG
JUHHQWRVKRZDQLQFUHDVHLQ3,137KHVHFRQG3,13YDOXHVKRXOGKDYHEHHQ
WDNHQDIWHUPRQWKVRIWUHDWPHQWDQGWKHEURNHQKRUL]RQWDOOLQHVKRZVWKH
FULWLFDOYDOXHRIǌJ/WKHPHDQYDOXHRI3,13LQKHDOWK\\RXQJZRPHQ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)LJXUH6KHIILHOG3,13PRQLWRULQJDOJRULWKPIRUDQDEROLFWUHDWPHQW$Q
RSWLPDOUHVSRQVHZRXOGEHDQLQFUHDVHLQ3,13RIPRUHWKDQXJ/WRDERYH
ȝJ/ 
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)LJXUH7KHDEVROXWHYDOXHRI3,13ǌJ/PHDVXUHGXVLQJ5RFKH&REDVDW
EDVHOLQHRQHDQGWKUHHPRQWKVDIWHUVWDUWLQJWHULSDUDWLGHLQSHRSOHIRU
RVWHRSRURVLV7KHEOXHGDVKHGKRUL]RQWDOOLQHUHSUHVHQWVWKHXSSHUOLPLWRIWKH
UHIHUHQFHLQWHUYDOIRUKHDOWK\\RXQJZRPHQǌJ/2YHUDOOUHVSRQGHG
ZLWKDQLQFUHDVHRIPRUHWKDQǌJ/DERYHEDVHOLQHDWERWKDQGPRQWKV
DQGH[FHHGHGWKHXSSHUOLPLWRIWKHUHIHUHQFHLQWHUYDODWDWOHDVWRQH
WLPHSRLQW3DWLHQWVPHHWLQJERWKUHVSRQVHFULWHULDLHGHPRQVWUDWLQJDQRSWLPDO
UHVSRQVHDUHVKRZQLQEODFNWKRVHZKRKDGDVLJQLILFDQWLQFUHDVHLQ3,13EXW
QRWH[FHHGLQJWKHUHIHUHQFHLQWHUYDODUHVKRZQLQUHG3DWLHQWVLQZKRPQR
%70UHVSRQVHZDVGHPRQVWUDWHGDUHVKRZQLQJUHHQ7KHH[WUHPHO\KLJKYDOXH
RI3,13RIPRUHWKDQǌJ/ZDVREVHUYHGLQDSDWLHQWZLWKDXWRLPPXQH
KHSDWLWLV 
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